Jonathan Wright, MD

Jonathan Wright, MD
Appointed 07/01/89
Women's Health Network
2276 Regional Oncology Center
750 East Adams Street
Syracuse, NY 13210
315 464-4353

Current Appointments

Hospital Campus

  • Downtown

Clinical Section Affiliations

  • Medicine: Hematology and Oncology
  • Upstate Cancer Center: Medical Oncology

Research Programs and Affiliations

  • Medicine

Education & Fellowships

  • Fellowship: Boston City Hospital, 1985, Hematology/Oncology
  • Residency: University of Kansas Medical Center, Kansas City, KS, 1981, Internal Medicine
  • MD: University of Kansas School of Medicine, 1978

Clinical Interests

  • Clinical research in gastrointestinal malignancies

Research Interests

  • Gastrointestinal malignancies

Clinical Trials

  • CALGB 80802: Phase III Randomized Study of Sorafenib (IND 69896, NSC 724772) Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
    Read more
  • CALGB 80803 - Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
    Read more

Specialties & Certification

  • Internal Medicine
  • Hematology
  • Oncology

Diseases & Conditions Treated

  • All Cancers and Hematological Conditions
  • Colon and Rectal Cancer
  • Stomach Cancer


  • Adults


  • Apheresis
  • Blood Transfusion
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Marrow Transplantation (BMT)
  • Chemotherapy
  • Conscious Sedation
  • Infusional Therapies
  • Lumbar Puncture
  • Paracentesis
  • Stem Cell Collection Procedures
  • Stem Cell Transplantation
  • Thoracentesis

Current Hospital Privileges

  • Upstate University Hospital


Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Research Abstract

Selected References

Scott, L.C., Yao, J.C., Benson III, A.B., Thomas, A.L., Falk, S., Mena, R.R., Picus, J., Wright, J., Mulcahy, M.F., Ajani, J.A., Evans, T.R.J.  A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction and adenocarcinoma. Cancer Chemother Pharmacol. 63:363-370, 2009

Vahdat, Linda T., Pruitt, Brian, Fabian, Carol J., Rivera, Ragene R., Smith, David A., Tan-Chiu, Elizabeth, Wright, Jonathan, Tan, Antoinette R., DaCosta, Noshir A., Chuang, Ellen, Smith, John, O'Shaughnessy, Joyce, Shuster, Dale E., Meneses, Nicole L., Chandrawansa, Kumari, Fang, Fang, Cole, Patricia E., Ashworth, Simon, and Blum, Joanne L.  Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J Clin. Oncol 27:2954-2961, 2009

Clinical Profile Shortcut:
Faculty Profile Shortcut: